Please assess the completion status of the following clinical trial:

Trial Title: Metabolic Resuscitation Using Ascorbic Acid, Thiamine, and Glucocorticoids in Sepsis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~i. Diagnosis of sepsis or septic shock within 12 hours of admission to the ICU ii. Informed consent as dictated by IRB and local practice. iii. Compliance with the 3 hour sepsis bundle~* 30ml/kg of intravenous crystalloid fluid (e.g.: sodium chloride 0.9%) for lactic acid \>4 and/or systolic blood pressure \<90mmHg / mean arterial pressure \<65mmHg~* Lactic acid level drawn~* Broad spectrum antibiotics given after obtaining blood cultures~Exclusion Criteria:~i. Age \< 18 years ii. Pregnant iii. DNR/DNI with limitations of care on admission iv. Patients with terminal end stage disease (i.e. stage IV cancer, end stage heart failure) that are unlikely to survive to hospital discharge v. Patients with a primary admitting diagnosis of an acute cerebral vascular event, acute coronary syndrome, active gastrointestinal bleeding, burn or trauma \[64-66\] vi. Requirement for immediate surgery \[64-66\] vii. Patients with HIV and a CD4 \< 50 mm2 \[64-66\] viii. Patients with known glucose-6 phosphate dehydrogenase (G-6PD) deficiency.\[39\] ix. Patients with sepsis/septic shock transferred from another hospital x. Patients with features of sepsis/septic shock \> 24 hours after admission

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): Based on published clinical data, vitamin C pharmacokinetic modeling, the package insert as well as the preliminary study by Marik et al, Vitamin C will be administered as an intravenous dose of 6gm per day divided in 4 equal doses. This dosage is reported to be devoid of any complications or side effects. Hydrocortisone will be dosed according to the consensus guidelines of the American College of Critical Care Medicine. Thiamine will be administered according to current recommendations in a dose of 200mg q 12 hourly. This will be continued for 4 days, or less if discharged from the ICU prior.
- Placebo Arm (Type: PLACEBO_COMPARATOR): Vitamin C placebo will consist of an identical bag of 100mL normal saline (but with no vitamin C) and will be labeled Vitamin C or Placebo. Placebo will be infused over 30 minutes as per the infusion instructions of the active vitamin and protected from light with a brown bag. Hydrocortisone placebo will be provided as an identical 3mL syringe as 1mL of normal saline.The thiamine placebo will be placed in a 50mL bag of Normal Saline labeled Thiamine 200mg or Placebo and run over 30 minutes (100mL/hr) Placebo patients will receive a matching 50mL bag of Normal Saline. All of these will be given for up to 4 days, or less if discharged from the ICU prior.

Based on this trial design, predict the completion outcome and termination type (if applicable).